Tags

Type your tag names separated by a space and hit enter

Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study.
Transfusion. 2007 Sep; 47(9):1691-9.T

Abstract

BACKGROUND

Transfusion of red blood cells (RBCs) has been associated with immunomodulatory effects. Persistence of donor cells in the recipient may be contributive.

STUDY DESIGN AND METHODS

A randomized single-center trial was conducted to compare microchimerism and immune responses in 35 patients undergoing cancer surgery and transfused perioperatively with either unmodified RBCs (UN-RBCs, n = 18) or leukoreduced RBCs (LR-RBCs, n = 17). Biologic parameters included microchimerism assessment peripheral blood mononuclear cell (PBMNC) phenotyping, cytokine production by stimulated PBMNCs, FoxP3 gene expression, and T-cell repertoire (TCR) analysis.

RESULTS

Microchimerism was documented in 8 of 18 patients after UN-RBC transfusion while absent after LR-RBC transfusion (0/17; p = 0.001). After UN-RBC transfusion, microchimerism was associated with increased interleukin (IL)-10 production (p = 0.02), reduced TCR alteration (p = 0.04), and reduced CD56+ cell counts (p = 0.02) when compared to recipients without evidence for microchimerism. FoxP3 gene expression did not differ significantly between both treatment groups nor with the presence or absence of microchimerism in the UN-RBC group. Finally, after an initial early decrease after surgery and transfusion, IL-12 production increased and more significantly so after UN-RBC transfusion versus LR-RBC transfusion (p = 0.05).

CONCLUSION

UN-RBC-induced microchimerism is associated with specific immunomodulatory effects in cancer patients who received transfusions during surgery.

Authors+Show Affiliations

Unit of Transfusion Medicine and Hemovigilance, the Biostatistics and Epidemiology Service, the Department of Anesthesia and Reanimation, Gustave Roussy Cancer Institute, Villejuif, France. valerie.lapierre@igr.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17725736

Citation

Lapierre, Valérie, et al. "Immune Modulation and Microchimerism After Unmodified Versus Leukoreduced Allogeneic Red Blood Cell Transfusion in Cancer Patients: Results of a Randomized Study." Transfusion, vol. 47, no. 9, 2007, pp. 1691-9.
Lapierre V, Aupérin A, Robinet E, et al. Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study. Transfusion. 2007;47(9):1691-9.
Lapierre, V., Aupérin, A., Robinet, E., Ferrand, C., Oubouzar, N., Tramalloni, D., Saas, P., Debaene, B., Lasser, P., & Tiberghien, P. (2007). Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study. Transfusion, 47(9), 1691-9.
Lapierre V, et al. Immune Modulation and Microchimerism After Unmodified Versus Leukoreduced Allogeneic Red Blood Cell Transfusion in Cancer Patients: Results of a Randomized Study. Transfusion. 2007;47(9):1691-9. PubMed PMID: 17725736.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study. AU - Lapierre,Valérie, AU - Aupérin,Anne, AU - Robinet,Eric, AU - Ferrand,Christophe, AU - Oubouzar,Nadia, AU - Tramalloni,Dominique, AU - Saas,Philippe, AU - Debaene,Bertrand, AU - Lasser,Philippe, AU - Tiberghien,Pierre, PY - 2007/8/30/pubmed PY - 2007/10/18/medline PY - 2007/8/30/entrez SP - 1691 EP - 9 JF - Transfusion JO - Transfusion VL - 47 IS - 9 N2 - BACKGROUND: Transfusion of red blood cells (RBCs) has been associated with immunomodulatory effects. Persistence of donor cells in the recipient may be contributive. STUDY DESIGN AND METHODS: A randomized single-center trial was conducted to compare microchimerism and immune responses in 35 patients undergoing cancer surgery and transfused perioperatively with either unmodified RBCs (UN-RBCs, n = 18) or leukoreduced RBCs (LR-RBCs, n = 17). Biologic parameters included microchimerism assessment peripheral blood mononuclear cell (PBMNC) phenotyping, cytokine production by stimulated PBMNCs, FoxP3 gene expression, and T-cell repertoire (TCR) analysis. RESULTS: Microchimerism was documented in 8 of 18 patients after UN-RBC transfusion while absent after LR-RBC transfusion (0/17; p = 0.001). After UN-RBC transfusion, microchimerism was associated with increased interleukin (IL)-10 production (p = 0.02), reduced TCR alteration (p = 0.04), and reduced CD56+ cell counts (p = 0.02) when compared to recipients without evidence for microchimerism. FoxP3 gene expression did not differ significantly between both treatment groups nor with the presence or absence of microchimerism in the UN-RBC group. Finally, after an initial early decrease after surgery and transfusion, IL-12 production increased and more significantly so after UN-RBC transfusion versus LR-RBC transfusion (p = 0.05). CONCLUSION: UN-RBC-induced microchimerism is associated with specific immunomodulatory effects in cancer patients who received transfusions during surgery. SN - 0041-1132 UR - https://www.unboundmedicine.com/medline/citation/17725736/Immune_modulation_and_microchimerism_after_unmodified_versus_leukoreduced_allogeneic_red_blood_cell_transfusion_in_cancer_patients:_results_of_a_randomized_study_ L2 - https://doi.org/10.1111/j.1537-2995.2007.01344.x DB - PRIME DP - Unbound Medicine ER -